Integra LifeSciences Holdings Corporation
Find Ratings ReportsINTEGRA LIFESCIENCES HOLDNGS's gross profit margin for the fourth quarter of its fiscal year 2023 is essentially unchanged when compared to the same period a year ago. Sales and net income have dropped, underperforming the average competitor within its subsector. INTEGRA LIFESCIENCES HOLDNGS has strong liquidity. Currently, the Quick Ratio is 1.88 which shows the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
During the same period, stockholders' equity ("net worth") has decreased by 11.99% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q4 FY23 | Q4 FY22 |
---|---|---|
Net Sales ($mil) | 396.04 | 398.42 |
EBITDA ($mil) | 100.0 | 110.1 |
EBIT ($mil) | 69.01 | 80.6 |
Net Income ($mil) | 19.83 | 52.95 |
Balance Sheet | Q4 FY23 | Q4 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 309.1 | 456.66 |
Total Assets ($mil) | 3781.99 | 3889.76 |
Total Debt ($mil) | 1681.68 | 1615.36 |
Equity ($mil) | 1587.88 | 1804.4 |
Profitability | Q4 FY23 | Q4 FY22 |
---|---|---|
Gross Profit Margin | 67.21 | 68.85 |
EBITDA Margin | 25.24 | 27.63 |
Operating Margin | 17.43 | 20.23 |
Sales Turnover | 0.41 | 0.4 |
Return on Assets | 1.79 | 4.64 |
Return on Equity | 4.27 | 10.01 |
Debt | Q4 FY23 | Q4 FY22 |
---|---|---|
Current Ratio | 3.45 | 3.62 |
Debt/Capital | 0.51 | 0.47 |
Interest Expense | 13.75 | 12.89 |
Interest Coverage | 5.02 | 6.25 |
Share Data | Q4 FY23 | Q4 FY22 |
---|---|---|
Shares outstanding (mil) | 78.17 | 83.65 |
Div / share | 0.0 | 0.0 |
EPS | 0.25 | 0.63 |
Book value / share | 20.31 | 21.57 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 614151.0 | 627603.0 |
HOLD. INTEGRA LIFESCIENCES HOLDNGS's P/E ratio indicates a discount compared to an average of 49.88 for the Miscellaneous Manufacturing subsector and a significant premium compared to the S&P 500 average of 27.95. For additional comparison, its price-to-book ratio of 1.72 indicates a significant discount versus the S&P 500 average of 4.68 and a significant discount versus the subsector average of 4.96. The price-to-sales ratio is well below both the S&P 500 average and the subsector average, indicating a discount. Upon assessment of these and other key valuation criteria, INTEGRA LIFESCIENCES HOLDNGS proves to trade at a discount to investment alternatives.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IART 41.99 | Peers 49.88 | IART 19.46 | Peers 33.16 | |||||||||||||||||||||
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations. IART is trading at a discount to its peers. |
Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. IART is trading at a significant discount to its peers. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
IART 9.63 | Peers 24.07 | IART 0.15 | Peers 0.91 | |||||||||||||||||||||
Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations. IART is trading at a significant discount to its peers. |
Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. IART trades at a significant discount to its peers. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
IART 1.72 | Peers 4.96 | IART -61.58 | Peers 126.83 | |||||||||||||||||||||
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. IART is trading at a significant discount to its peers. |
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. However, IART is expected to significantly trail its peers on the basis of its earnings growth rate. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
IART 1.75 | Peers 6.41 | IART 0.04 | Peers 8.91 | |||||||||||||||||||||
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. IART is trading at a significant discount to its subsector on this measurement. |
Lower. A sales growth rate that trails the subsector implies that a company is losing market share. IART significantly trails its peers on the basis of sales growth. |
|||||||||||||||||||||||